chevron_leftBack
As of 13 June 2026, Protara Therapeutics, Inc. has a market cap of $279.62M USD, ranking #19005 globally and #3160 in the United States.
It ranks #1716 in the Healthcare sector, and #628 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$279.62MUSD
Enterprise Value
$84.81MUSD
EBITDA (TTM)
-$64.19MUSD
Net Income (TTM)
-$57.44MUSD
PB Ratio
1.4
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Jesse Shefferman
open_in_new
Employees
46
Website
protaratx.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 2.2% | -4.4% | 4.7% | -28% | 1.6% | 47% |
News
Loading...
TARA Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
TARA
Protara Therapeutics Inc Ordinary Shares
ISIN: US74365U1079
Shares Out.:
Shares Outstanding:
56.204M1
Shares Float:
50.61M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
5.17 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
272K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
196K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
129K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
98K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
53K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
42K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
115K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
103K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
98K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
65K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
39K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
39K%
80.96B GBP
|
14.6
|
chevron_leftBack